← All trials
NCT06294600
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 12, 2024
- Primary completion
- Nov 5, 2025
- Completion date
- Jan 30, 2026
- First posted
- Mar 5, 2024
- Last posted
- Oct 23, 2024
- Enrollment
- 330
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Hellenic Institute for the Study of SepsisLead sponsor
- Hellenic Sepsis Study GroupOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.